Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.
Sandor Schoichet
Advertisement
Articles by Sandor Schoichet
Meaningful biopharma sustainability metrics are a crucial challenge.
Biopharma sustainability resolutions for a better 2021.
Why major companies are stepping up environmental commitments.
SynBio opens new environmental sustainability possibilities for pharma.
Biopharma must find sustainable models for public policy engagement.
ESG objectives are integral to long-term biopharma strategy.
The need for clear transparency around use of real-world data, AI.
Advertisement
Latest Updated Articles
Why ESG Performance Metrics MatterPublished: March 11th 2021 | Updated:
Pharma’s Digital-Trust MandatePublished: August 7th 2020 | Updated:
The Regulatory Engagement ConundrumPublished: October 14th 2020 | Updated:
A New Year for Sustainable GovernancePublished: January 13th 2021 | Updated:
- Sustainable Long-Term Planning
Published: September 11th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
